Acucela Announces End of Treatment Period in Phase 2b/3 Clinical Trial of Emixustat Hydrochloride

SEATTLE--(BUSINESS WIRE)--Acucela Inc. (Tokyo: 4589) (“Acucela”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, announced today the completion of the treatment period in the ongoing Phase 2b/3 clinical trial, the S.E.A.T.T.L.E. study, of the investigational visual cycle modulator emixustat hydrochloride (emixustat). The study enrolled 508 patients with geographi

Full Story →